Result of Assessment of Small molecule Protein-Protein Interaction (PPI) Inhibitors Designed by Interprotein
Published: Nov 28, 2012
The compounds designed by Interprotein were assessed at Takeda for binding to the target protein at the molecular level, and approximately 11%*) of the compounds tested were confirmed to bind to the target protein. Takeda will proceed with further evaluation of the compounds based on the results.
*) It is generally recognized that hit rates of compounds against protein targets through computational drug design methods are well below 11%.
Hirotsugu KOMATSU, Ph.D.